RT Journal Article
SR Electronic
T1 Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1701
OP 1708
VO 34
IS 4
A1 TAKASHI YAMAMURA
A1 NAOYUKI MATSUMOTO
A1 YASUYOSHI MATSUE
A1 MICHISATO OKUDERA
A1 YOUICHI NISHIKAWA
A1 YOSHIMITSU ABIKO
A1 KAZUO KOMIYAMA
YR 2014
UL http://ar.iiarjournals.org/content/34/4/1701.abstract
AB Aim: Tumor angiogenesis is a focus of molecularly-targeted therapies. This study investigated the effect of sodium butyrate (SB), a histone deacetylase inhibitor, on the synthesis of antiangiogenic and lymphangiogenic factors in oral squamous cell carcinoma. Design: Gene alterations in HSC-3 cells were assessed using cDNA microarrays before and after treatment with SB. The mRNA and protein expression of lymphangiogenic factors were also assessed by quantitative PCR, western blotting and immunocytochemistry. Results: Microarray analysis revealed that treatment with SB led to altered expression of angiogenesis-related gene expression. The quantitative polymerase chain reaction showed that platelet-derived growth factor-B, angiopoietin-2, vascular endothelial growth factor (VEGF)-C, and VEGFD were down-regulated. Western blotting and immunocytochemistry confirmed reduced protein synthesis of VEGFC. Conclusion: SB inhibits expression of lymphangiogenic factors in HSC-3 cells. Within the limitations of the present study, SB may have potential as an anti-metastatic pro-drug for oral cancer.